other material
confidence high
sentiment neutral
materiality 0.50
Esperion Therapeutics discloses preliminary cash balance of $82M as of Dec 29, 2023
Esperion Therapeutics, Inc.
- Preliminary cash, cash equivalents and short-term investments total $82.0M as of December 29, 2023.
- Amount is preliminary and subject to completion of financial closing procedures.
- Full quarterly and year-end financial results for December 31, 2023 not yet released.
- Ernst & Young has not audited or reviewed this preliminary data.